Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
Researchers found that early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) at 2 years or less leads to significant and sustained improvements in disease activity.
According to study results presented at the American College of Rheumatology (ACR) Convergence 2025, outcomes were comparable to patients who received treatment later in life and those not exposed to TNF inhibitors.
The study used data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023 to describe the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.
Early initiation of TNF inhibitors leads to significant improvements in disease activity.
Author's summary: Early TNF inhibitor use improves nonsystemic JIA outcomes.